Clinical research
Clinical Trial Results from MyoKardia’s Phase 2 PIONEER-HCM Study of Mavacamten Published in the Annals of Internal Medicine
While few drug developers are focused on multi-drug resistant invasive fungal infections, San Diego-based Cidara Therapeutics is in the thick of the fight with its Phase III lead antifungal rezafungin.
The company indicated it was dropping LY2606368, prexasertib, a CHK1 drug in Phase II, and LY3023414, a PI3k/mTOR inhibitor that was also in Phase II.
MorphoSys AG and I-Mab Biopharma announced that the first patient has been dosed in a phase 3 randomized and multi-center clinical study in Taiwan to evaluate MorphoSys’s investigational human CD38 antibody MOR202/TJ202 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.
Ireland-based Horizon Pharma reported additional statistically significant secondary data from its positive Phase III study at a conference and plans to continue to share analysis at future medical conferences.
Novo Nordisk announced positive results from its ELLIPSE Phase III clinical trial of Victoza (liraglutide) in treating type 2 diabetes in children aged 10 to 17. The company presented the results at the Pediatric Endocrine Society (PES)/Pediatric Academic Societies (PAS) Annual Meeting held in Baltimore, MD, and simultaneously published in the New England Journal of Medicine.
As a monotherapy, Keytruda showed non-inferiority to standard of care but missed the mark as a combination treatment.
Eli Lilly and Company announced that as it withdraws Lartruvo (olaratumab) from the market for treatment of advanced soft tissue sarcoma (STS), it is establishing an Access Program for patients currently receiving the drug who may wish to continue.
Companies across Europe and Asia provide information about deal, clinical trials and more, with news from Synaptive Medical, Epic, Inventiva, Velabs, and more.
MorphoSys AG, Galapagos NV and Novartis Pharma AG announced the initiation of GECKO, a phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.
PRESS RELEASES